BLACK DIAMOND THERAPEU

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

09 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

09 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference

06 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer

01 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference

17 May 2022 06:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

12 May 2022 15:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

11 May 2022 15:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment

25 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

18 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference

07 Apr 2022 15:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors

07 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

17 Mar 2022 16:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

02 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

22 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

11 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022

10 Jan 2022 06:00:02 By Nasdaq GlobeNewswire